Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
5.93
-0.27 (-4.35%)
At close: Mar 9, 2026, 4:00 PM EDT
6.00
+0.07 (1.18%)
After-hours: Mar 9, 2026, 5:22 PM EDT

Company Description

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.

It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.

The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.

Anteris Technologies Global Corp. is based in Toowong, Australia.

Anteris Technologies Global Corp.
Anteris Technologies Global logo
Country Australia
Founded 1999
IPO Date Dec 13, 2024
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 174
CEO Wayne Paterson

Contact Details

Address:
Toowong Tower, Level 3, Suite 302
Toowong, QLD 4066
Australia
Phone 61 7 3152 3200
Website anteristech.com

Stock Details

Ticker Symbol AVR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0002011514
ISIN Number US03675P1021
SIC Code 3842

Key Executives

Name Position
Wayne Geoffrey Paterson Vice Chairman and Chief Executive Officer
David St. Denis President and Director
Matthew McDonnell Chief Financial Officer
Dr. Chris Meduri M.D., M.P.H. Chief Medical Officer and Member of Medical Advisory Board

Latest SEC Filings

Date Type Title
Mar 3, 2026 8-K Current Report
Feb 27, 2026 8-K Current Report
Feb 26, 2026 10-K Annual Report
Feb 13, 2026 SCHEDULE 13G/A Filing
Feb 5, 2026 SCHEDULE 13G/A Filing
Jan 29, 2026 SCHEDULE 13D Filing
Jan 23, 2026 424B3 Prospectus
Jan 22, 2026 8-K Current Report
Jan 22, 2026 8-K Current Report
Jan 22, 2026 424B5 Filing